Optimization of viral protein ratios for production of rAAV serotype 5 in the baculovirus system

47Citations
Citations of this article
98Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Recombinant adeno-associated virus (rAAV) has become the vector of choice for the development of novel human gene therapies. High-yield manufacturing of high-quality vectors can be achieved using the baculovirus expression vector system. However, efficient production of rAAV in this insect cell-based system requires a genetic redesign of the viral protein 1 (VP1) operon. In this study, we generated a library of rationally designed rAAV serotype 5 variants with modulations in the translation-initiation region of VP1 and investigated the potency of the resulting vectors. We found that the initiation strength at the VP1 translational start had downstream effects on the VP2/VP3 ratio. Excessive incorporation of VP3 into a vector type decreased potency, even when the VP1/VP2 ratio was in balance. Finally, we successfully generated a potent rAAV vector based on serotype 5 with a balanced VP1/VP2/VP3 stoichiometry.

Cite

CITATION STYLE

APA

Bosma, B., du Plessis, F., Ehlert, E., Nijmeijer, B., de Haan, M., Petry, H., & Lubelski, J. (2018). Optimization of viral protein ratios for production of rAAV serotype 5 in the baculovirus system. Gene Therapy, 25(6), 415–424. https://doi.org/10.1038/s41434-018-0034-7

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free